You can buy or sell BauschHealth and other stocks, options, ETFs, and crypto commission-free!
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. Read More The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
52 Week High
52 Week Low
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
Shares of Bausch Health Companies Inc . BHC were up 8.4% after it raised sales guidance for 2019. However, the company reported mixed results for the first quarter of 2019. The company's adjusted earnings per share of $1.03 beat the Zacks Consensus Estimate of 89 cents and increased from 90 cents reported in the year-ago quarter.
Yahoo FinanceMay 7
See what the IHS Markit Score report has to say about Bausch Health Companies Inc.
Bausch Health Companies Inc NYSE:BHC View full report here! Summary Perception of the company's creditworthiness is positive and improving ETFs holding this stock are seeing positive inflows but are weakening Bearish sentiment is low Economic output in this company's sector is expanding Bearish sentiment Short interest | Positive Short interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not cur...
The Motley FoolMay 6
Bausch Health Companies Inc. (BHC) Q1 2019 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC) Q1 2019 Earnings Call , 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and welcome to the Bausch Health 1Q19 Earnings Conference Call. All participants will be in listen-only mode. (Operator Instructions) After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) Please note, this event is being recorded. I now would like to turn the call over to...
Expected Aug 6, Pre-Market